Preventing prostate cancer: new analyses put finasteride back on the map.
Vastag
Brian
B
D058891:5-alpha Reductase Inhibitors; D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001378:Azasteroids / Q000627:therapeutic use; D015982:Bias; D001707:Biopsy, Needle; D002273:Carcinogens; D015986:Confounding Factors, Epidemiologic; D017277:Drug Approval; D000068538:Dutasteride; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D018120:Finasteride / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D008297:Male; D010330:Patents as Topic; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control*; D012720:Severity of Illness Index; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
D058891:5-alpha Reductase Inhibitors; D016588:Anticarcinogenic Agents; D001378:Azasteroids; D002273:Carcinogens; D004791:Enzyme Inhibitors; D018120:Finasteride; D000068538:Dutasteride